6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2024 in “Acta dermato-venereologica”
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
21 citations
,
October 2023 in “Journal of Dermatological Treatment” Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
May 2018 in “Dermatologic Surgery”
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
April 2018 in “Journal of Investigative Dermatology” Fetuin A may increase collagen production and promote scarring.
1 citations
,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
6 citations
,
September 2024 in “BMC Pulmonary Medicine” Cepharanthine may help treat lung fibrosis by affecting certain immune cells.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
1 citations
,
July 2022 in “British Journal of Dermatology” Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
1 citations
,
January 2023 in “Cutis” You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
December 2023 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
18 citations
,
October 2017 in “Drug Design Development and Therapy” DA-9401 helps protect rat testis from finasteride damage.
15 citations
,
April 2011 in “The journal of investigative dermatology/Journal of investigative dermatology” A3B5 can reduce skin pigmentation and slow melanoma growth.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
5 citations
,
July 2024 in “Archives of Dermatological Research” 10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.